Ethos Technologies Inc. (LIFE) fair value analysis
Nasdaq · Updated 2026-10-26
LIFE price how computed
Valuation status
Awaiting full valuationLIFE's estimate rests on a sector-average price-to-earnings multiple, not on its own validated earnings history.
TickrTrends does not publish a borrowed multiple as a verdict. A verdict publishes automatically once LIFE's own trailing P/E history validates; every covered stock is re-evaluated weekly.
- Last price
- $43.10
- Sector
- Financial Services
- 12-month range
- $11.13–$43.10
- Market cap
- $2.8B
- From 52-week high
- 0.0%
- Shares outstanding
- 65M
- Rank in Financial Services by quality score
- #42 of 208
Last price is our stored weekly price from 2026-10-23, older than the 2026-10-26 run that built this page; the chart runs through 2026-10-23.
Ethos Technologies Inc. operates a digital life insurance platform that enables consumers to shop for and purchase life insurance policies online. The company serves customers throughout the United States.
LIFE currently ranks #42 of 208 Financial Services stocks by quality score.
Fundamentals (4 quarters) how computed
- Market cap
- $2.8B
- P/E (trailing)
- 31x
- Revenue (TTM)
- $587M
- Net margin
- -18.1%
- EPS (TTM)
- $1.37
- Gross margin
- 96.2%
- Debt / equity
- 0.04
- Shares outstanding
- 65M
Derived indicators how computed
- Quality grade
- B
- 52-week position
- The top quarter of its range
Technicals how computed
- RSI (14-day)
- 69 · neutral
Earnings how computed
- Next earnings report
- 2026-11-02 (post-market)
- Last 8 quarters vs consensus
- 7 beat, 1 missed
- Quarter by quarter
- 2026-06 ▲ beat (+57.9%)
2026-03 ▼ miss (-19.1%)
2025-12 ▲ beat (+4.7%)
2025-09 ▲ beat
2024-03 ▲ beat (+4.2%)
2023-12 ▲ beat (+8.0%)
2023-09 ▲ beat (+9.1%)
2022-12 ▲ beat (+45.8%)
Analyst consensus how computed
This is not TickrTrends' verdict.
- Analyst ratings
- 9 buy · 0 hold · 0 sell (9 analysts)
- Consensus lean
- Buy-leaning
- Consensus price target
- $37.5
- Target vs last price
- -13.0%
What our data shows for LIFE
- Our model validated 1 trailing price-to-earnings windows for LIFE, built from quarterly earnings records.
- Shares are trading in the upper third of their 12-month price range of $11.13–$43.10.
- The 14-day relative strength index sits at a neutral 69.
What subscribers see
- Every published Forward Fair Value with its exact discount or premium
- The normalized P/E and quarter count behind each estimate
- Screeners and rankings across the full S&P 500 and Nasdaq universes
- LIFE's own verdict the week it qualifies, published automatically
Forward Fair Value applies a conservatively normalized historical price-to-earnings multiple to the consensus earnings estimate for the next full fiscal year; how TickrTrends computes it.
Recent LIFE news
TickrTrends' derived news-sentiment signal for LIFE is currently leaning positive, computed from recent coverage.
- FEDERATED HERMES, INC. Trims aTyr Pharma Inc (ATYR) Stake -- Shares Trade 61% Below GF Value (gurufocus.com, 2026-10-14)
- ATYR Looks 27.8% Undervalued on GF Value™ as Phase 3 Trial Framework Confirmed (gurufocus.com, 2026-09-24)
- aTyr Pharma Announces Alignment with FDA on Phase 3 Study of Efzofitimod in Pulmonary Sarcoidosis (manilatimes.net, 2026-09-24)
What people are saying
Follow the LIFE conversation: Stocktwits · Reddit · X
TickrTrends weekly updates
- 2026-10-26 — No material change this week: the verdict, bands and grades all held steady.
- 2026-10-19 — No material change this week: the verdict, bands and grades all held steady.
- 2026-10-12 — No material change this week: the verdict, bands and grades all held steady.
- 2026-10-11 — No material change this week: the verdict, bands and grades all held steady.
- 2026-10-10 — TickrTrends' quality grade for LIFE declined from A to B this week. The Financial Services sector company's derived indicators reflected this downgrade in their assessment of the company's fundamental quality metrics. The valuation verdict remains awaiting full valuation at this time.
- 2026-10-05 — No material change this week: the verdict, bands and grades all held steady.
- 2026-09-28 — No material change this week: the verdict, bands and grades all held steady.
- 2026-09-21 — No material change this week: the verdict, bands and grades all held steady.
Frequently asked questions
Is LIFE stock undervalued?
LIFE's estimate rests on a sector-average price-to-earnings multiple rather than its own validated earnings history, and TickrTrends does not publish a borrowed multiple as a verdict. It is re-evaluated every week.
What is LIFE's TickrTrends verdict?
LIFE is currently marked 'Awaiting full valuation' - a verdict publishes automatically once LIFE's own trailing P/E history validates under our standards.
How does LIFE compare to other Financial Services stocks?
LIFE ranks #42 of 208 Financial Services stocks in TickrTrends' coverage by quality score. It carries no fair-value verdict yet, so it is not ranked by discount.
Is LIFE overbought or oversold?
LIFE's 14-day RSI is in neutral territory - neither overbought nor oversold.
When does LIFE report earnings next?
LIFE's next earnings report is scheduled for 2026-11-02 (post-market), per the published earnings calendar.
Does LIFE usually beat earnings estimates?
Over its last 8 reported quarters LIFE beat the consensus estimate 7 times and missed 1 times, by TickrTrends' comparison of reported and estimated EPS.
What do analysts say about LIFE?
Of 9 analysts covering LIFE, 9 rate it a buy, 0 a hold and 0 a sell - buy-leaning, with a consensus price target of $37.5 (-13.0% versus TickrTrends' last price). This is the analyst consensus, not TickrTrends' Forward Fair Value verdict.